TRexBio raises $84M to take in-house immune program into the clinic

Lei Lei Wu

News Reporter

Bay Area immunology biotech TRexBio has raised a $84 million Series B to start clinical studies of a potential treatment for atopic dermatitis and ulcerative …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRexBio raises $84M to take in-house immune program into the clinic

Lei Lei Wu

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

US warns drugmakers against misrepresenting cost of imported products

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

TRexBio rais­es $84M to take in-house im­mune pro­gram in­to the clin­ic

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRexBio raises $84M to take in-house immune program into the clinic